Pancreatic adenocarcinoma tumor antigens (PDAC antigens)

Pancreatic adenocarcinoma tumor antigens (PDAC antigens) are a heterogeneous group of proteins and peptides that are overexpressed, mutated, or aberrantly presented by pancreatic ductal adenocarcinoma cells. These antigens, which include mesothelin, mucin 1 (MUC1), carcinoembryonic antigen (CEA), and mutant KRAS, serve as the primary targets for modern immunotherapeutic interventions such as cancer vaccines, chimeric antigen receptor (CAR) T-cell therapies, and bispecific antibodies. Biologically, many of these antigens contribute to the aggressive phenotype of pancreatic cancer by promoting cell adhesion, signaling, and immune evasion within the dense, desmoplastic tumor microenvironment. While they offer a pathway for high-precision therapy, the clinical utility of targeting these antigens is often hampered by the profoundly immunosuppressive nature of the pancreatic stroma and the risk of on-target, off-tumor toxicity in healthy tissues that express low levels of the same proteins. Ongoing research focuses on identifying novel neoantigens and cryptic peptides to improve the specificity and efficacy of treatments for this highly lethal malignancy.

Other names

Pancreatic cancer-associated antigensPDAC tumor-associated antigensPancreatic ductal adenocarcinoma antigensPancreatic cancer neoantigens

Immune activation via vaccination, T-cell redirection (CAR-T), monoclonal antibody-mediated cytotoxicity (ADCC), and direct inhibition of oncogenic protein function.